Pay in 4 interest-free payments of $7.16 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
About this article Cite this article Agarwal, A., Sengupta, P
Regardless of pathway, GLP-1 medications require evaluation and monitoring by licensed healthcare providers
MACE-5 (all-cause death, MI, stroke, heart failure event, coronary revascularisation) 44 events on retatrutide, 52 on placebo: In-study: HR 0.82 (95% CI 0.551.22) On-treatment: HR 0.73 (95% CI 0.471.12) MACE-3 (CV death, MI, stroke) 27 events on retatrutide, 23 on placebo: In-study: HR 1.12 (95% CI 0.641.96) On-treatment: HR 0.92 (95% CI 0.511.65) Lilly states plainly that MACE occurred less frequently than anticipated in both arms
Explaining why GLP-1 drugs improve health without weight loss defies simple narratives and confounds researchers
What Did Retatrutides Phase 3 Trials Find
Biallelic variants in TAMM41 are associated with low muscle cardiolipin levels, leading to neonatal mitochondrial disease
US$ 25.46
US$ 24.85
US$ 22.75
US$ 20.63
US$ 24.32
US$ 23.34
US$ 25.39
US$ 22.95
